Phase 3 eventuates from a Ph...

Phase 3

eventuates from a Phase 3 inquiry published in the March issue of Pediatrics, demonstrate that Metadate CD (Celltech Pharmaceuticals, Inc., Rochester, NY methylphenidate HCl USP) Extended-Release Capsules (CII), 20 mg when administered one time daily before school, can reign over attention deficit hyperactivity disorder (ADHD) symptoms during the exercise day without the need for a secondary midday dose. The primary efficacy measure was the difference in severity of ADHD symptoms from baseline upon the teacher version of Conners' Global Index. The mean improvement from baseline was